Aarti Drugs Limited (NSE:AARTIDRUGS) — Stock Price
Aarti Drugs Limited (NSE:AARTIDRUGS) is currently trading at Rs427.40 INR, down 2.25% today. Over the past 52 weeks, shares have ranged between Rs319.75 and Rs524.60. This page tracks Aarti Drugs Limited's live share price on the NSE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see AARTIDRUGS company net worth.
Aarti Drugs Limited (AARTIDRUGS) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Aarti Drugs Limited's daily closing share price and trading volume on the NSE exchange over the past year, giving a clear view of recent price momentum and liquidity.
Aarti Drugs Limited Income Statement — Revenue, Profit & Earnings by Year
Aarti Drugs Limited's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Total Revenue | Rs25.65 Billion | Rs23.87 Billion | Rs25.29 Billion | Rs27.16 Billion | Rs24.89 Billion |
| Cost of Revenue | Rs18.15 Billion | Rs15.42 Billion | Rs16.78 Billion | Rs18.89 Billion | Rs21.00 Billion |
| Gross Profit | Rs7.50 Billion | Rs8.45 Billion | Rs8.51 Billion | Rs3.69 Billion | Rs3.89 Billion |
| Research & Development | — | Rs130.42 Million | Rs120.21 Million | Rs94.38 Million | Rs78.21 Million |
| SG&A | Rs991.67 Million | Rs1.12 Billion | Rs1.02 Billion | Rs921.40 Million | Rs827.03 Million |
| Total Operating Expenses | Rs5.08 Billion | Rs1.12 Billion | Rs1.17 Billion | Rs1.04 Billion | Rs2.06 Billion |
| Operating Income | Rs2.42 Billion | Rs7.33 Billion | Rs2.69 Billion | Rs2.65 Billion | Rs2.88 Billion |
| EBITDA | Rs3.12 Billion | Rs2.87 Billion | Rs3.25 Billion | Rs3.12 Billion | Rs3.44 Billion |
| EBIT | Rs2.45 Billion | Rs2.31 Billion | Rs2.73 Billion | Rs2.61 Billion | Rs2.94 Billion |
| Interest Expense | Rs337.10 Million | Rs358.70 Million | Rs378.88 Million | Rs371.38 Million | Rs239.08 Million |
| Income Before Tax | Rs2.11 Billion | Rs2.12 Billion | Rs2.36 Billion | Rs2.24 Billion | Rs2.70 Billion |
| Income Tax Expense | Rs159.60 Million | Rs436.80 Million | Rs639.37 Million | Rs578.20 Million | Rs649.59 Million |
| Net Income | Rs1.95 Billion | Rs1.68 Billion | Rs1.71 Billion | Rs1.66 Billion | Rs2.05 Billion |
Aarti Drugs Limited Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Aarti Drugs Limited's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Total Assets | Rs28.15 Billion | Rs25.75 Billion | Rs24.32 Billion | Rs24.21 Billion | Rs22.08 Billion |
| Total Current Assets | Rs14.68 Billion | Rs13.38 Billion | Rs13.21 Billion | Rs14.92 Billion | Rs13.93 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | Rs154.70 Million | Rs150.50 Million | Rs21.86 Million | Rs122.10 Million | Rs126.40 Million |
| Net Receivables | Rs8.31 Billion | Rs7.52 Billion | Rs7.05 Billion | Rs8.65 Billion | Rs7.63 Billion |
| Inventory | Rs4.91 Billion | Rs4.73 Billion | Rs4.86 Billion | Rs5.16 Billion | Rs5.26 Billion |
| Property, Plant & Equipment | — | — | — | Rs8.86 Billion | Rs7.67 Billion |
| Goodwill | — | — | Rs-58.00K | Rs8.00K | — |
| Total Liabilities | Rs12.66 Billion | Rs12.05 Billion | Rs11.50 Billion | Rs12.29 Billion | Rs11.72 Billion |
| Total Current Liabilities | Rs9.22 Billion | Rs8.37 Billion | Rs7.96 Billion | Rs9.33 Billion | Rs9.40 Billion |
| Long-term Debt | Rs2.57 Billion | Rs2.84 Billion | Rs2.75 Billion | Rs2.05 Billion | Rs1.39 Billion |
| Net Debt | Rs5.68 Billion | Rs6.08 Billion | Rs5.58 Billion | Rs6.00 Billion | Rs5.21 Billion |
| Total Stockholder Equity | Rs15.49 Billion | Rs13.69 Billion | Rs12.82 Billion | Rs11.92 Billion | Rs10.36 Billion |
| Retained Earnings | Rs14.00 Billion | Rs12.40 Billion | Rs11.55 Billion | Rs10.21 Billion | Rs8.79 Billion |
Aarti Drugs Limited Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Aarti Drugs Limited generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | Rs2.22 Billion | Rs2.45 Billion | Rs3.59 Billion | Rs1.34 Billion | Rs696.36 Million |
| Capital Expenditures | Rs1.73 Billion | Rs1.77 Billion | Rs2.26 Billion | Rs1.65 Billion | Rs1.52 Billion |
| Free Cash Flow | Rs490.90 Million | Rs674.20 Million | Rs1.33 Billion | Rs-304.70 Million | Rs-823.39 Million |
| Investing Cash Flow | Rs-1.75 Billion | Rs-1.65 Billion | Rs-2.24 Billion | Rs-1.64 Billion | Rs-1.49 Billion |
| Financing Cash Flow | Rs-451.40 Million | Rs-821.20 Million | Rs-1.36 Billion | Rs165.40 Million | Rs920.25 Million |
| Dividends Paid | Rs181.70 Million | Rs90.60 Million | Rs92.67 Million | Rs94.00 Million | Rs95.08 Million |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | Rs669.70 Million | Rs557.80 Million | Rs514.47 Million | Rs503.20 Million | Rs500.49 Million |
| Change in Cash | Rs36.63 Million | Rs-21.63 Million | Rs-7.61 Million | Rs-132.30 Million | Rs127.99 Million |
Aarti Drugs Limited Earnings History — EPS Actual vs. Analyst Estimates
Track Aarti Drugs Limited's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Jul 31, 2026 | 5.66 | 5.40 | +4.81% |
| May 04, 2026 | — | — | — |
| Jan 27, 2026 | — | — | — |
| Nov 07, 2025 | 4.95 | 4.90 | +1.02% |
| Jul 24, 2025 | — | — | — |
| May 06, 2025 | — | — | — |
| Jan 22, 2025 | — | — | — |
| Oct 23, 2020 | 8.07 | 5.78 | +39.62% |